WO2017058003A2 - Method of isolating mesenchymal stromal cells and applications for tissue engineering - Google Patents
Method of isolating mesenchymal stromal cells and applications for tissue engineering Download PDFInfo
- Publication number
- WO2017058003A2 WO2017058003A2 PCT/MY2016/050063 MY2016050063W WO2017058003A2 WO 2017058003 A2 WO2017058003 A2 WO 2017058003A2 MY 2016050063 W MY2016050063 W MY 2016050063W WO 2017058003 A2 WO2017058003 A2 WO 2017058003A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- tissue
- tissue sample
- culture media
- incubated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/09—Means for pre-treatment of biological substances by enzymatic treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the invention relates to a method of isolating mesenchymal stromal cells, particularly for use in research following subsequent expansion and differentiation thereof.
- Mesenchymal stromal cells are stem cells which are able to develop into a variety of cell types, although as they are pluripotent (as opposed to totipotent), not an embryo that could develop into an organism. As a result, mesenchymal stromal cells are the subject of much research, and a good source of the same is highly desirable.
- An aim of the invention is therefore to provide an isolation method which overcomes these difficulties.
- tissue sample at least 3 times; incubating the tissue sample in a solution comprising at least one antibiotic and at least one antimycotic at a temperature of around 28-38°C and atmosphere comprising about 4-6% C0 2 ;
- tissue sample incubating the tissue sample in collagenase dissolved in DMEM-KO at a temperature of around 28-38°C and atmosphere comprising about 4-6% CO2 to produce a solution of tissue fragments;
- MSC culture media is added to the tissue sample during the collagenase incubation to quench the action of the collagenase such that the tissue sample is only partially digested.
- the MSC culture media is added when the tissue sample is transparent but still substantially solid and not yet liquefied by the collagenase.
- the initial washing of the tissue sample is with sterile distilled water.
- the at least one antibiotic comprises penicillin and streptomycin in PBS.
- Trypsin-EDTA is added to the solution of tissue fragments and incubated at 28-38 ° C, 4-6% CO2 for around 5 minutes to detach cells from the matrix.
- the tissue fragments in MSC culture media are incubated in a low oxygen hypoxia or CO2 incubator for about 24 hours to promote growth of cells. Typically the MSC culture media is repeatedly replaced until the cells reach about 70- 80% confluency.
- the expansion steps can be repeated several times to progress the cells from passage 0 to passage 3, wherein a final product is formed on resuspending the pellet.
- the final product undergoes cryopreservation.
- the tissue sample is derived from umbilical cord, foreskin or cornea.
- the arteries, veins and blood components are removed from the umbilical cord while minimising the loss of the Wharton's jelly therefrom.
- this decreases contamination by erythrocytes, as well as any other cells, cell fragments or derivatives thereof from umbilical vein (eg HUVEC).
- the prior art method does not involve complete removal of vein and arteries and also results in accidental removal of the matrix substance which produces decreased/inferior cell yield.
- the umbilical cord is processed in about 3-5 separate segments.
- this minimizes contamination, provides replicate samples, and reduces the consumables required due to the higher surface area:volume ratio.
- the prior art methods involve the whole umbilical cord being processed as a single sample whereby erythrocytes, fibrinogen, fibrin, cell debris, cell contents etc., from a region of the cord can act as contaminants during tissue incubation which accelerates microbial contamination.
- the tissue sample is typically incubated in about 1-5% (w/v), preferably around 3% (w/v) collagenase type IV for approximately 10-12 hours.
- the tissue sample is typically incubated in about 1-5% (w/v), preferably around about 1-5% (w/v), preferably around 3% (w/v) collagenase type IV for approximately 4-10 hours.
- the tissue sample is typically incubated in about 1-5% (w/v), preferably around 3% (w/v) collagenase type IV for approximately 2-4 hours.
- the tissue sample is dental pulp.
- the initial washing of the tissue sample is with Dulbecco's phosphate buffered saline without calcium or magnesium.
- the dental pulp is extirpated from a freshly extracted deciduous tooth.
- the tooth is sectioned horizontally at the cementoenamel junction using a sterilized diamond disc while being irrigated with saline or distilled water.
- tissue sample is typically incubated in about 1-5% (w/v), preferably around 3% (w/v) collagenase type I for about 30 minutes.
- the incubation of tissue samples is conducted at a temperature of around 37°C and atmosphere comprising about 5% CO2.
- a tooth holder comprising:
- the chuck including three jaws and a collar, whereby rotation of the collar extends or retracts the jaws thereby adjusting the aperture size between the jaws to allow a tooth to be held thereby; irrigation means above the chuck for dripping liquid onto the tooth;
- the chuck includes a central channel through which liquid may be pumped.
- the jaws are provided with grooves or steps to allow for precise measurement and placement of the tooth.
- genes and respective primer pairs are selected from SEQ ID Nos: 1 and 2; 3 and 4; 5 and 6; 7 and 8; and/or 9 and 10.
- genes which are dopaminergic neuronal markers, indicates that the cells are mesenchymal stromal cells capable of creating a dopaminergic cell line that can be used a research grade product e.g. for Parkinson's disease research.
- sample of cells is a final product.
- tissue or product made by differentiating mesenchymal stromal cells produced by the method as herein described.
- a dopaminergic cell, neuron or derivative thereof made by differentiating mesenchymal stromal cells produced by the aforementioned method.
- a corneal tissue made by differentiating corneal limbal cells derived from mesenchymal stromal cells derived from a cornea tissue sample according to the aforementioned method. Typically cornea tissue can be grown in different layers to form a cornea.
- This skin tissue may be used for foreskin restorative surgery or human skin grafts, e.g. for use in treating burn victims.
- Figure 1 illustrates different types of mesenchymal stromal cells in the respective finished products.
- Figure 2 illustrates the ability of different types of mesenchymal stromal cells to form aggregates/neurospheres in NIM media.
- Figure 3 illustrates the results of semi-quantitative RT-PCR analysis of the expression of certain genes for immunophenotyping of mesenchymal stromal cells
- Figure 4 illustrates immunocytochemistry of different types of mesenchymal stromal cells
- Figure 5 illustrates a tooth holder according to an embodiment of the invention Detailed Description
- Umbilical cord should be clamped ideally within 30 to 60 seconds following birth of the infant placed.
- the clamp is placed at or below the level of the placenta to allow optimal blood transfer from the placenta to the infant.
- Sterile surgical blades or any other sterile cutting instruments or implement are used to cut the umbilical cord cut into three to five segments and placed into 50ml polypropylene conical centrifuge tubes pre-added with 25ml of transport buffer stored at 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C. This entire process should be done in a labour room with temperature ranging from 20 °C to 25 °C and the umbilical cord must be placed into the transport buffer within 24 hours upon birth to maintain tissue viability.
- the umbilical cord is then transported to the laboratory for mesenchymal stromal cell isolation process. Components of transport buffer are as described in Table 1 below.
- the umbilical cord is processed in a Class II Biological Safety Cabinet (BSC) with following environment conditions; room temperature (25°C ⁇ 5), relative humidity (65% ⁇ 10).
- BSC Class II Biological Safety Cabinet
- the following process is carried out entirely in a BSC sterilized with 70% ethanol and 30 minutes UV radiation.
- the 50ml polypropylene conical centrifuge tubes containing segmented umbilical cords are wiped with 70% ethanol.
- Tables 2-3 below are used for the cleaning process.
- PBS Phosphate buffered saline
- the cord Upon transportation of the umbilical cord to the laboratory, the cord is segmented into 5 parts and the segmented cord is transferred into five individual 50ml polypropylene conical centrifuge tubes pre-added with 30ml SDW. Segmented cords are washed by inverting the tubes repeatedly to remove blood traces to prevent blood contamination. This step is repeated at least three times to ensure the cords are thoroughly washed using fresh SDW and 50ml polypropylene conical centrifuge tubes. The segmented cords are transferred to the surgical tray to remove blood clots and traces of any components contained within blood including but not limited to neutrophils, lymphocytes, plasma, and erythrocytes. This is to prevent blood, blood related products, and any other products from causing contamination.
- Umbilical cord contains two umbilical arteries and one umbilical vein, both embedded within a specific mucous proteogly can-rich matrix which is known as Wharton's Jelly, which is then covered by amniotic epithelium.
- the umbilical arteries and vein are carefully removed by means of dissection without losing the matrix substance in which most of the Wharton's Jelly Stem Cells (WJSCs) are found.
- WJSCs can be isolated from three regions of the umbilical cord, namely, the perivascular zone, the inter-vascular zone and the sub-amnion.
- the cord is then immersed in 70% ethanol for 25 to 30 second to sterilize the surface and immediately immersed into SDW for another 25 to 30 seconds to remove ethanol residues and create an immediate hypotonic environment on the cord's surface to eliminate microbes.
- the cords are then transferred into five individual 50ml polypropylene conical centrifuge tubes pre-added with 25ml 10% v/v Antibiotic-Antimycotic and 10% v/v Penicillin-Streptomycin in PBS.
- the tubes are incubated at around 28-38°C, about 4-6% CO2 for around 2-16 hours, preferably 37 ° C, 5% CO2 for 2 hours/overnight.
- the incubator is programmed at around 28-38°C, about 4-6% CO2, preferably at 37 ° C, 5% CC to provide an optimal environment for the cord tissues/cells to maintain viability.
- each segmented cord Prior to incubation, each segmented cord is washed with PBS twice for 30 to 60 seconds, to remove traces of Antibiotic-Antimycotic and Penicillin-Streptomycin.
- the cords are cut into small pieces (2-5mm) and transferred to a fresh 50ml polypropylene conical centrifuge tubes containing 20ml of 3% w/v collagenase type IV dissolved in DMEM-KO.
- Cords are allowed to be partially digested at around 28-38°C, about 4-6% CO2 for around 2-16 hours, preferably 37 ° C, 5% CO2 for 10 to 12 hours.
- Trypsin-EDTA is added into the partially digested cord and incubated at 37 ° C, 5% CO2 for 5 minutes to detach cells from the matrix.
- 20ml of MSC culture media is added into each tubes and centrifuged at about 1500-2500rpm, 700-1000g force/RCF, for around 8-12minutes, at about 25-28°C, preferably about 1800rpm for 10 minutes at 25°C. It is crucial to neutralize the enzymatic action as cell viability will reduce if Trypsin is allowed to stay in contact with the cells for too long. Prior to centrifugation, 50% of the supernatant is carefully removed by pipetting to eliminate excess MSC culture media and Trypsin.
- Undigested semi-transparent umbilical cord fragments from the tubes are picked using sterile tissue forceps and transferred into 60mm cell culture plate. The process is repeated till all umbilical cord fragments are transferred and left to air dry for 15minutes in the BSC. This step is to ensure the tissues are attached to the culture plate surface. Upon adherence of the cord tissue fragments onto the culture plate, 5-7ml of MSC culture media is added gently without disrupting the attached tissues. The MSC culture media provides sufficient nutrients and an optimal environment for the survival of the tissues. Culture plates are then transferred to a CO2 incubator or low oxygen hypoxia incubator and incubated for around 16-36 hours, preferably about 24 hours.
- Tooth structure can be divided into two parts anatomically, namely the crown and the root, separated by the cementoenamel junction (CEJ).
- the CEJ is the crown part that consists of enamel, dentin and pulp chamber.
- the anatomic root is located below the CEJ that is covered with cementum and also has a pulp canal in the root area.
- Dental pulp consists of loose connective tissue that is confined within the pulp chamber and root canals of the tooth.
- the composition of a dental pulp is by weight 75% water and 25% organic material comprised of a plentiful matrix of cells.
- Cells such as odontoblasts, fibroblasts, undifferentiated ectomesencyhmal cells, macrophages and other immunocompetent cells are the principal fibres that can be found within the dental pulp.
- Cells within the pulp provide the mature pulp with odontogenic, nutritive, sensory and defensive functions that allow for the preservation of vitality during normal homeostatic maintenance and post injury repair and regeneration.
- Odontoblasts are highly specialized cells that are responsible for the secretion and mineralization of the fibrillar extracellular matrix of dentin. Fibroblasts are important in formation and maintenance of the pulp matrix consistency of collagen. Undifferentiated ectomesenchymal cells are found throughout the pulp core which is therefore a source of material for stromal cell applications. Extraction of dental pulp from tooth
- An intra-oral examination is done to assess the pulp status of the subjects.
- Samples are collected from the pulp tissue that is extirpated from freshly extracted deciduous teeth.
- the extracted deciduous tooth is kept in a specimen container filled with normal saline to maintain the moisture content within the tooth.
- the cutting of the tooth and extirpation of the dental pulp tissue should commence as soon as possible after tooth extraction from the subject.
- Extracted teeth are sterilized externally with Povidone iodine (PVP-I, Sigma Aldrich, St Louis, USA) and washed with distilled water to minimize the contaminants from the tooth surface contaminating the extirpated dental pulp tissue.
- PVP-I Povidone iodine
- a tooth holder is used to hold the teeth securely, as illustrated in Figure 5.
- the tooth holder comprises a modified circular rotating drill chuck 2 with three jaws 4 fixed to a stainless steel base 6.
- the drill chuck includes a central channel 8 through which water may be pumped via tube 10 to deploy saline or distilled water to the tooth and for cleaning the device.
- the jaws 10 may be extended or retracted via rotation of the collar 12, which also alters the aperture size at the tips of the jaws to allow a tooth 14 to be gripped firmly.
- the jaws may be provided with grooves 16 or steps to allow for precise measurement and placement of the tooth to optimize dental pulp extirpation. Water may be also dripped from a tube 18 located above the chuck 2.
- the tooth is sectioned horizontally at the cementoenamel junction using a sterilized diamond disc straight hand piece to expose the pulp.
- Extirpation of the dental pulp tissue is done under aseptic conditions. Copius irrigation with saline or distilled water is provided throughout the procedure which acts as a lubricant during and throughout the process, and also serves to reduce the amount of heat generated from the cutting process. This minimizes the destruction of tissue from heat.
- the dental pulp tissue is then transferred into a 1.5 ml tube containing DMEM Knock Out Basal Media (Gibco, Grand Island, NY). The extirpated pulp tissue sample is immediately sent to the laboratory for isolation process.
- Dental pulp tissues are processed in a Class II Biological Safety Cabinet (BSC) with the following environment conditions; room temperature (25°C ⁇ 5), relative humidity (65% ⁇ 10). The following process is carried out entirely in a BSC sterilized with 70% ethanol and 30 minutes UV radiation. The 1.5ml microcentrifuge tubes containing dental pulp tissues are wiped with 70% ethanol. The dental pulp tissues are washed three times in a washing buffer solution that contains Dulbecco's Phosphate-Buffered Saline without calcium and magnesium (DPBS -Ca 2+ , -Mg 2+ , Invitrogen, USA), 0.85% of penicillin-streptomycin and 0.85% of antibiotic-antimycotic.
- BSC Class II Biological Safety Cabinet
- the tissue is minced into small fragments prior to Collagenase Type I treatment (Gibco, Grand Island, NY). After that, the tissue is incubated at 37°C for 30 minutes. Next, the tissue is transferred into the 15 ml tube (BD Bioscience, Franklin Lakes, NJ, USA) containing 8 ml of MSC culture media. The tissue is centrifuged for 6 minutes at 1250 rpm. The supernatant is discarded and the pellet is gently resuspended with 10 ml of MSC culture media. Then, the cells are seeded in a T25 culture flask together with the growth media and incubated in a 5% CO2 incubator humidified with 95% of air or using a low oxygen hypoxia incubator.
- a 5% CO2 incubator humidified with 95% of air or using a low oxygen hypoxia incubator.
- the medium is replaced every three days and monitored for any signs of contamination. After the primary culture becomes confluent in approximately 10-20 days, cells are collected by trypsinization using 0.05% Trypsin-EDTA (Gibco, invitrogen) and processed for subsequent subcultures.
- Trypsin-EDTA Gibco, invitrogen
- Foreskin fibroblast-like stromal cells are progenitors isolated from human tissue that can differentiate into many cell types. These cells are mainly found on the dermis of the foreskin.
- Human foreskin is obtained from neonates, children, teenagers or adults of male sex during circumcision and placed into sterile 50ml polypropylene conical centrifuge tubes pre-added with 25ml of transport buffer stored at 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C. This entire process should be done in a room with temperature ranging from 20°C to 25°C and the foreskin must be placed into the transport buffer solution within 24 hours to maintain tissue viability. The foreskin is then transported to the laboratory for mesenchymal stromal cell isolation.
- Foreskin tissues are processed in a Class II Biological Safety Cabinet (BSC) with the following environment conditions; room temperature (25°C ⁇ 5), relative humidity (65% ⁇ 10). The following process is carried out entirely in a BSC sterilized with 70% ethanol and 30 minutes UV radiation.
- the 50ml polypropylene conical centrifuge tubes containing the foreskin tissues are wiped with 70% ethanol.
- the sample is then transferred into a 50ml polypropylene conical centrifuge tubes pre-added with 30ml SDW. The sample is washed by inverting the tubes repeatedly to remove traces of blood and to prevent any contamination.
- This step is repeated at least three times to ensure the foreskin is thoroughly washed using fresh SDW in a 50ml polypropylene conical centrifuge tube.
- the foreskin is then immersed in 70% ethanol for 25 to 30 seconds to sterilize the surface and immediately immersed into SDW for another 25 to 30 seconds to remove ethanol residues and create an immediate hypotonic environment on the skin's surface to eliminate microbes.
- the tissue is then transferred into a 50ml polypropylene conical centrifuge tubes pre-added with 25ml 10% v/v Antibiotic- Antimycotic and 10% v/v Penicillin-Streptomycin in PBS.
- the tubes are incubated at around 28-38°C, about 4-6% C0 2 for around 2-16 hours, preferably 37 ° C, 5% CO2 for 2 hours/overnight.
- the incubator is programmed at 37 ° C, 5% CCh to provide an optimal environment for the cord tissues/cells to maintain viability.
- the sample Prior to incubation, the sample is washed with PBS twice for 30 to 60 seconds, to remove traces of Antibiotic-Antimycotic and Penicillin-Streptomycin.
- the foreskin is then cut into small pieces (2-5mm) and transferred to a fresh 50ml polypropylene conical centrifuge tubes containing 20ml of 3% w/v collagenase type IV dissolved in DMEM-KO.
- the sample is allowed to be partially digested at around 28-38°C, about 4- 6% CO2, preferably 37 ° C, 5% CO2, for 4 to 10 hours.
- Trypsin-EDTA 400 ⁇ 1 of 0.25% Trypsin-EDTA is added into the partially digested sample and incubated at 37 ° C, 5% CO2 for 5 minutes to detach cells from the tissue.
- 20ml of MSC culture media is added into the tube and centrifuged at about 1500-2500rpm, 700-1000g force/RCF, for around 8-12minutes, at about 25-28°C, preferably about 1800rpm for 10 minutes at 25°C. It is crucial to neutralize the enzymatic action as cell viability will be reduced if Trypsin remains in contact with the cells for too long (typically it should not exceed 15 minutes).
- Corneal limbal epithelial stromal cells is a non-keratinized epithelium composed of a cluster of cells with a capacity for self-renewal. These cells are localized at the basal cell layer of the limbus which is responsible for the regeneration of corneal epithelium and to maintain the cornea. CLSCs differ from the corneal epithelial cells due to the lack of corneo-specifie d fferentiation keratins (K3/K 12) expression, eonnexin 43-mediated gap junction intercellular communication, p63 nuclear transcription factor, cell cycle duration, and label retaining properties.
- K3/K 12 corneo-specifie d fferentiation keratins
- Human corneal tissue obtained via any form of keratoplasty surgery done for patients with keratoconus, corneal scarring, Fuchs' dystrophy, Lattice dystrophy and other cornea related diseases which requires cornea transplantation, or human corneal tissue obtained in any other manner, is placed into a sterile 50ml polypropylene conical centrifuge tubes pre-added with 25ml of transport buffer stored at 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C. This entire process should be done in a room with temperature ranging from 20 °C to 25 °C and the corneal tissue must be placed into the transport buffer within 24 hours of the procedure to maintain tissue viability. The cornea tissue is then transported to the laboratory for stromal cell isolation.
- Corneal tissues is processed in a Class II Biological Safety Cabinet (BSC) with the following environment conditions; room temperature (25°C ⁇ 5), relative humidity (65% ⁇ 10). The following is carried out entirely in a BSC sterilized with 70% ethanol and 30 minutes UV radiation.
- the 50ml polypropylene conical centrifuge tubes containing the cornea tissues are wiped with 70% ethanol.
- the sample is then transferred into a 50ml polypropylene conical centrifuge tube pre-added with 30ml SDW.
- the sample is washed by inverting the tubes repeatedly to prevent contamination. This step is repeated at least three times to ensure the tissue is thoroughly washed using fresh SDW and 50ml polypropylene conical centrifuge tubes.
- the tissue is transferred into a 50ml polypropylene conical centrifuge tube pre-added with 25ml 10% v/v Antibiotic-Antimycotic and 10% v/v Penicillin-Streptomycin in PBS.
- the tube is incubated at 37 ° C, 5% CO2 for 2 hours/overnight.
- the incubator is programmed at 37 ° C, 5% CO2 to provide an optimal environment for the cord tissues/cells to maintain its viability.
- the sample Prior to incubation, the sample is washed with PBS twice for 30 to 60 seconds, to remove traces of Antibiotic- Antimycotic and Penicillin-Streptomycin.
- the tissue is then cut into small pieces (2-5mm) and transferred to a fresh 50ml polypropylene conical centrifuge tubes containing 20ml of 3% w/v collagenase type IV dissolved in DMEM- KO.
- the sample is allowed to be partially digested at around 28-38°C, about 4-6% CO2, preferably 37 ° C, 5% CO2, for 2 to 4 hours.
- Trypsin-EDTA 400 ⁇ 1 of 0.25% Trypsin-EDTA is added into the partially digested sample and incubated at around 28-38°C, about 4-6% CO2, preferably 37 ° C, 5% CO2, for 5 minutes to detach cells from the tissue.
- 20ml of MSC culture media is added into the tube and centrifuged at about 1500-2500rpm, 700-1000g force/RCF, for around 8-12minutes, at about 25-28°C, preferably about 1800rpm for 10 minutes at 25°C. It is crucial to neutralize the enzymatic action as cell viability will be reduced if Trypsin remains in contact with the cells for too long.
- MSC culture media Prior to centrifugation, 50% of the supernatant is carefully removed by pipetting to eliminate excess MSC culture media and Trypsin. Undigested tissue fragments and the remaining MSC culture media from the tube are aspirated into 60mm cell culture plate. An additional 5-7ml of MSC culture media is added into the culture plate. The MSC culture media provides sufficient nutrients and optimal environment for the survival of the tissues. The culture plates are then transferred to a CO2 incubator or a low oxygen hypoxia incubator and incubated for 24 hours. After 24 hours incubation, 2/3 of the media is pipetted out gently without disrupting adhered tissues and replaced with fresh MSC culture media.
- the culture plates are transferred back to the CO2 incubator and an additional 5ml of fresh MSC culture media is added in the next 24 hours for continuous supply of nutrients for cell growth and also to remove dead or apoptotic cells from the culture.
- the culture is observed using an inverted microscope every day and 2/3 of media is replaced every 2 to 4 days until the cells reach 80% confluency until subcultured to passage 1 stock. 80% cell confluency is used as the end point for each passage to maintain cultures with optimal cell numbers and viability.
- MSCs EXPANSION OF MESENCHYMAL STROMAL CELLS
- a Class II BSC Prior to subculture from passage 0 to passage 1 of MSCs derived from umbilical cord, dental pulp, foreskin and cornea, a Class II BSC with following environment conditions; room temperature (25°C ⁇ 5), relative humidity (65% ⁇ 10), is sterilized with 70% ethanol and 30 minutes UV radiation.
- the 60mm cell culture plates with 80% confluence cells are transferred from the CO2 incubator to the BSC. Culture media is pipetted out completely and the culture plate is washed with 10ml PBS (without Magnesium and Calcium ions) twice. Each culture plate is gently swirled 10 to 15 times during washing process and the remaining PBS is pipetted out.
- MSCs cells are seeded into T175 culture flask at a 1500cells/cm 2 seeding density with the addition of 15ml of MSC culture media and the flasks are moved forward and back gently to cause the cells to spread evenly.
- the remaining cells at passage 0 are then cryopreserved as MSCs SCO.
- the flasks containing MSCs SCI are then incubated at 37°C in 5% humidified CO2 incubator or low oxygen hypoxia incubator. Every 3 days cells are observed under inverted microscope and 8ml of MSC culture media are replaced until cells reach 80% confluency. Upon reaching 80% confluency, WJSC SCI cell cultures are sub-cultured into passage 2.
- a Class II BSC Prior to subculture MSCs from passage 1 to passage 2 a Class II BSC with following environment conditions; room temperature (25°C ⁇ 5), relative humidity (65% ⁇ 10) are sterilized with 70% ethanol and 30 minutes UV radiation.
- the T175 flasks with 80% confluence cells are transferred from the CO2 incubator to the BSC. Spent media is aspirated out completely and washed with 20ml PBS (without Magnesium and Calcium ions) twice. Each of the flasks is gently swirled several times during washing process and remaining PBS is aspirated out. 5ml of pre warmed TrypLETM Express is added into each flasks and incubated at 37 ° C, 5% CO2 until cells detach.
- MSCs suspension from T175 flasks is transferred through pipetting into 50ml polypropylene conical centrifuge tubes each. The tubes are centrifuged at about 1000-1250rpm, for around 5-7 minutes, at about 25- 28°C, preferably about 1200rpm for 6 minutes at 25°C. The supernatant is discarded and cell pellets are re-suspended with 5ml of pre-warmed MSC culture media.
- MSCs are seeded into T175 culture flask at a 1500cells/cm 2 seeding density for optimal cell proliferation while reducing the chances of inducing biological stress into the cell population. 15ml of MSC culture media are then added the flasks are moved forward and back gently to cause and ensure that the cells spread evenly. Remaining cells at passage 1 are cryopreserved as MSCs SCI . The flasks containing MSCs SC2, are then incubated at 37°C in a 5% humidified CO2 incubator or with a low oxygen hypoxia incubator. The cells are observed under inverted microscope every 2 to 4 days and 8ml of MSC culture media is replaced during each observation. This process is repeated until cells reach 80% confluency. Upon reaching 80% confluency, MSCs SC2 cell cultures are sub-cultured into passage 3 as a finished product.
- a Class II BSC Prior to subculture MSCs from passage 2 to passage 3 a Class II BSC with following environment conditions; room temperature (25°C ⁇ 5), relative humidity (65% ⁇ 10) is sterilized with 70% ethanol and 30 minutes UV radiation.
- the T175 flasks with 80% confluence cells are transferred from CO2 incubator to the BSC. Spent media is aspirated out completely and the T175 flask is washed with 20ml PBS (without Magnesium and Calcium ions) twice. Each of the flasks are gently swirled several times during washing process and remaining PBS is aspirated out.
- the tubes are centrifuged at about 1000-1250rpm, for around 5-7 minutes, at about 25-28°C, preferably about 1200rpm for 6 minutes at 25°C. The supernatant is discarded and cell pellets are re-suspended with 5ml of pre-warmed MSC culture media. Upon performing a cell count, cells at passage 3 (MSCs SC3) are prepared for cryopreservation.
- cryopreservation media Prior to cryopreservation of MSCs finished product at passage 3 a Class II BSC with following environment conditions; room temperature (25°C ⁇ 5), relative humidity (65% ⁇ 10) is sterilized with 70% ethanol and 30 minutes UV radiation. Freezing media is used as cryopreservation media.
- the appropriate volume of freezing media is prepared fresh according to the formula in Table 4 below:
- Freezing media is not allowed to be exposed to light and is kept at 4°C ⁇ 2 - this is to negate the effects of light on DMSO.
- Cryovials are sterilized using 70% ethanol and labelled using a permanent cryo marker pen.
- MSCs SC3 pellets in 50ml polypropylene conical centrifuge tubes are gently exposed to desired volume of cold Freezing media by using a micropipette. Cells are carefully re-suspended to avoid gas bubble formation. The desired volume of cell suspension is transferred into pre-labelled cryovials. Freezing density and required volume of freezing media are illustrated in Table 5. Table 5
- Cryovials are immediately transferred to a -80°C freezer for 24 hours and finally kept in liquid nitrogen cryotank the following day. Cryovials are kept at -80°C freezer to allow for a gradual cooling process to occur (l°C/minute) till the vials reach -50°C prior to the vials being transferred into a liquid nitrogen cryotank. This is to reduce intracellular crystal formation thereby maintaining the optimal amount of viable cells. Location and details of each cryovial stored are recorded to ease the retrieval process.
- Immunophenotyping was carried out via flow cytometry at SC3. Upon reaching 80% confluency, the cells were harvested using 0.05% trypsin-EDTA (Invitrogen) and resuspended in Dulbecco's Phosphate Buffer Saline (DPBS; Invitrogen) at a cell density of 1.5xl0 6 cells/mL. Two hundred microliters of the cell suspension (3xl0 5 cells) were incubated with the labelled antibodies in the dark for 1 hour at 37°C. Antibodies conjugated to fluorochromes are susceptible to photobleaching and should be protected from light during all phases of an experiment.
- CD90-phycoerythrin PE
- CD44-PE CD73-PE
- CD166- PE and CD34-PE CD45-fluoroisothiocyanate
- FITC CD45-fluoroisothiocyanate
- HLA-DR-FITC HLA-DR-FITC
- Adipogenic lineage is stimulated by inducing the cells with 10% FBS, 200 mmol/L indomethacin, 0.5 mmol/L 3-isobutyl-l- methyxanthine (IB MX), 10 mg/mL insulin, and 1 mmol/L dexamethasone (all reagents from Sigma Aldrich). Lipid droplets are visualized by staining with oil red O staining (Sigma Aldrich).
- ITS+1 Sigma Aldrich
- 50 mmol/L L-ascorbic acid-2 phosphates Sigma Aldrich
- 55 mmol/L sodium pyruvate Invitrogen
- 25 mmol/L L-proline Sigma Aldrich
- 10 ng/mL of transforming growth factor-beta TGF-b
- TGF-b transforming growth factor-beta
- the osteogenic differentiation is stimulated in a 3-week culture in media supplemented with 10% FBS, 100 ⁇ /L dexamethasone, 10 mmol/L b-glycerol phosphate (Fluka, Buchs, Switzerland), and 100 mmol/L of L-ascorbic acid-2 phosphates. Assessment of calcium accumulation is visualized by von Kossa staining. WJSCs, SHED, FDSCs and CLSCs were able to differentiate into chondrogenic, adipogenic and osteogenic lineages in vitro).
- NAM neural-inducing medium
- D-MEM/ F-12 (1 : 1) 6000 mg/L D- glucose
- KnockOut SR 2 mM L-glutamine
- MEM non-essential amino acids solution 0.1 mM b-mercaptoethanol
- N2 supplement all from Gibco BRL
- the EBs are aspirated to super-hydrophilic plates (Costar, Cambridge, MA) in Neurobasal A media (GIBCO/Invitrogen, Carlsbad, CA) and supplemented with B27 (Invitrogen, Carlsbad, CA), 20 ng/mL basic fibroblast growth factor (bFGF; Invitrogen) and 20 ng/mL epidermal growth factor (EGF; Invitrogen).
- B27 Invitrogen, Carlsbad, CA
- B27 Invitrogen, Carlsbad, CA
- bFGF basic fibroblast growth factor
- EGF epidermal growth factor
- Fresh culture medium including EGF and bFGF is added to the medium after 4-5 days of culture.
- the EBs were induced with a cocktail of 200 ng/mL sonic hedgehog (SHH), 100 ng/mL fibroblast growth factor 8 (FGF8), 10 ng/mL glial cell line-derived neurotrophic factor (GD F; R&D Systems, Minneapolis, MN), and 10 ⁇ forskolin (PeproTech EC, London, England).
- SHH sonic hedgehog
- FGF8 fibroblast growth factor 8
- GD F ng/mL glial cell line-derived neurotrophic factor
- PeproTech EC London, England
- MSCs derived from WJSCs, SHED, FDSCs and CLSCs are able to form cell aggregates/neurospheres in NFM media.
- neurite outgrowth was only observed in SHED, FDSCs and CLSCs aggregates/neurospheres.
- RNA is isolated using TRIZOL method (Invitrogen), as per the manufacturer's protocol.
- the RNA is then quantified using a spectrophotometer (Agilent, NanoDrop, Technologies Inc.) and the purity is assessed by the absorbance value at ratio of 260:280 nm.
- the RNA is stored at -80°C.
- the first-strand complementary DNA (cDNA) is synthesized using 1 mg RNA treated with RNase-OUT ribonuclease inhibitor and the Superscript II First Strand Synthesis system (Invitrogen) according to the manufacturer's instructions. PCR is performed in 0.2 mL Eppendorf tubes (Axygen) with a final volume to 12.5 mL.
- cDNA amplification is performed in a thermocycler using Taq polymerase supplied with KC1 buffer and 1.5mM MgCk (Invitrogen) at 94°C for 1 min, 58°C for 30 s and 72°C for 1 min.
- PCR products are resolved on 1.5% agarose (Invitrogen) gel run in lx Tris borate- EDTA buffer.
- the primer sequences are listed in Table 7.
- the expressions of some genes in the semi -quantitative RT-PCR analysis are quantified in duplicate, using SYBR Green Master Mix (Applied Biosystems). PCR reactions are performed on an ABI 7900HT RT-PCR system (Applied Biosystems) and SDS v 2.1 software was used to analyse the results and to prove the immunophenotyping characteristics. All measurements are normalized to 18s rRNA. Table 7:
- Cells from respective sources are fixed for 20 min in 4% ice cold paraformaldehyde, treated with 0.1% Triton-X for optimal penetration of cell membranes, and incubated at room temperature (RT) in a blocking solution (0.5% BSA; Sigma Aldrich) for 30 min.
- the immunocytochemistry results show that WJSCs, SHED, FDSCs and CLSCs express Tyrosine hydroxylase (TH), ⁇ -tubulin, Nestin and Glutamate decarboxylase 65 and 65 (GAD65/67) protein post dopaminergic neuron-like differentiation.
- TH Tyrosine hydroxylase
- ⁇ -tubulin ⁇ -tubulin
- Glutamate decarboxylase 65 and 65 Glutamate decarboxylase 65 and 65
- SHED and WJSCs are the best candidates for any therapeutic application for dopaminergic neuronal degenerative disease.
- Cells obtained from the protocol described herein are able to retain 83% to 89% of viability (non-apoptopic) at passage 3.
- Prior art percentages achieved at passage 3 are around 70%-80% viability using 4% trypan blue exclusion method.
- usage of the 4% trypan blue exclusion method includes cell in late and early apoptosis as being viable, and as such, is not an accurate means of counting for cell viability.
- the method used is more accurate, namely the Annexin V apoptosis detection method by flow cytometry, to find out the exact percentage of non-apoptotic cells, excluding early and late apoptotic cells.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Sustainable Development (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3017103A CA3017103A1 (en) | 2015-10-02 | 2016-09-30 | Method of isolating mesenchymal stromal cells and applications for tissue engineering |
SG11201806561UA SG11201806561UA (en) | 2015-10-02 | 2016-09-30 | Method of isolating mesenchymal stromal cells and applications for tissue engineering |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI2015002493 | 2015-10-02 | ||
MYPI2015002493 | 2015-10-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017058003A2 true WO2017058003A2 (en) | 2017-04-06 |
WO2017058003A3 WO2017058003A3 (en) | 2017-05-04 |
Family
ID=58423898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MY2016/050063 WO2017058003A2 (en) | 2015-10-02 | 2016-09-30 | Method of isolating mesenchymal stromal cells and applications for tissue engineering |
Country Status (3)
Country | Link |
---|---|
CA (1) | CA3017103A1 (en) |
SG (1) | SG11201806561UA (en) |
WO (1) | WO2017058003A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019123407A1 (en) | 2017-12-22 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Mesenchymal stromal cells and methods for obtaining mesenchymal stromal cells from umbilical cord |
CN110577930A (en) * | 2019-09-30 | 2019-12-17 | 重庆赛托斯创生物科技发展有限公司 | Multi-connected-tube adipose-derived stem cell extraction method |
CN113604430A (en) * | 2021-09-06 | 2021-11-05 | 郑州源创吉因实业有限公司 | Method for culturing dental pulp mesenchymal stem cells |
WO2022056991A1 (en) * | 2020-09-16 | 2022-03-24 | 生物岛实验室 | Mesenchymal stem cells derived from umbilical cord, and preparation method therefor and use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7451990B2 (en) * | 2004-04-29 | 2008-11-18 | Jacobs Chuck Manufacturing Company | Chuck with torque indicator |
WO2012117333A1 (en) * | 2011-02-28 | 2012-09-07 | Stempeutics Research Malaysia Sdn Bhd | Isolation and expansion of adult stem cells, their therapeutic composition and uses thereof |
KR101385374B1 (en) * | 2012-10-29 | 2014-04-14 | 신현진 | A jig for processing artificial tooth |
-
2016
- 2016-09-30 WO PCT/MY2016/050063 patent/WO2017058003A2/en active Application Filing
- 2016-09-30 SG SG11201806561UA patent/SG11201806561UA/en unknown
- 2016-09-30 CA CA3017103A patent/CA3017103A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019123407A1 (en) | 2017-12-22 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Mesenchymal stromal cells and methods for obtaining mesenchymal stromal cells from umbilical cord |
CN110577930A (en) * | 2019-09-30 | 2019-12-17 | 重庆赛托斯创生物科技发展有限公司 | Multi-connected-tube adipose-derived stem cell extraction method |
WO2022056991A1 (en) * | 2020-09-16 | 2022-03-24 | 生物岛实验室 | Mesenchymal stem cells derived from umbilical cord, and preparation method therefor and use thereof |
CN113604430A (en) * | 2021-09-06 | 2021-11-05 | 郑州源创吉因实业有限公司 | Method for culturing dental pulp mesenchymal stem cells |
Also Published As
Publication number | Publication date |
---|---|
SG11201806561UA (en) | 2018-09-27 |
WO2017058003A3 (en) | 2017-05-04 |
CA3017103A1 (en) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8703411B2 (en) | Cryopreservation of umbilical cord tissue for cord tissue-derived stem cells | |
US20230092739A1 (en) | Stem cell compositions and methods of producing stem cells for therapeutic applications | |
La Torre et al. | Production and transplantation of retinal cells from human and mouse embryonic stem cells | |
WO2017058003A2 (en) | Method of isolating mesenchymal stromal cells and applications for tissue engineering | |
WO2009061024A1 (en) | Method for isolating and culturing adult stem cells derived from human amniotic epithelium | |
TW201827592A (en) | A method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells | |
ES2360434B1 (en) | PLURIPOTENTIAL MOTHER CELLS OBTAINED FROM THE DENTAL PULP. | |
CN111492051A (en) | Mesenchymal stromal cells and method for obtaining mesenchymal stromal cells from umbilical cord | |
Ma | Biomaterials and regenerative medicine | |
López et al. | Evaluating the impact of oxygen concentration and plating density on human wharton's jelly-derived mesenchymal stromal cells | |
KR20120140197A (en) | Testicular somatic cell-derived multipotent stem cells, process for the preparation thereof, and pharmaceutical composition for treating erectile dysfunction comprising the same | |
JP5833126B2 (en) | Amniotic fluid-derived multipotent stem cells and method for producing the same | |
KR102428120B1 (en) | A novel composition for stem cell culture | |
US10542743B2 (en) | Isolation, expansion and characterization of wharton's jelly mesenchymal stem cells | |
CN102533641B (en) | External serum-free adult stem cell amplifies the method and nutrient solution thereof cultivated | |
EP3875580A1 (en) | Methods for preparing keratinocytes | |
US20150164947A1 (en) | Novel adult progenitor cell | |
TWI836505B (en) | A method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord | |
Casella | Gene Expression Analysis of Rat Adi-pose Tissue-Derived Stem Cells | |
Rathore et al. | Isolation and culture of putative mesenchymal stem cells from the equine amniotic membrane | |
KR20150042535A (en) | Mesenchymal Stem Cells Drived from Nasal polyp and Method for Isolating the Same | |
Phruksaniyom et al. | Effect of Culture Conditions on Colony-Forming Ability of Stem Cells from Human Exfoliated Deciduous Teeth. | |
Pistillo | Human chorionic villus, amniotic fluid and amniotic membrane: Three different gestational tissues as source of valuable mesenchymal stem cells for regenerative medicine applications | |
Torbey | Stem cells in the oral cavity | |
Rathore et al. | Expression of reprogramming factors in mesenchymal stem cells isolated from equine umbilical cord Wharton’s jelly and amniotic fluid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16852148 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201806561U Country of ref document: SG |
|
ENP | Entry into the national phase in: |
Ref document number: 3017103 Country of ref document: CA |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16/08/2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16852148 Country of ref document: EP Kind code of ref document: A2 |